上述"调研清单"清晰地勾勒出当前外资在A股市场的关注焦点，即以AI为代表的科技和医药两大赛道。 高盛在近日发布的报告中表示，DeepSeek-R1的发布在2025年引发了中国科技公司的强劲反弹。从基本 面来看，高盛估计，未来十年，通过节约成本、提高生产率和创造新的收入机会，AI的广泛应用有望 推动企业盈利每年增长3%。 2025年以来，近800家外资机构合计调研A股上市公司近万次。其中，Point 72资产管理公司以263次调 研位居榜首；高盛、美银证券等国际大行的调研次数也均超过百次。从调研方向来看，科技和医药是外 资机构最为关注的两大赛道。 年内外资调研A股近万次 数据显示，截至12月26日，今年以来共有798家外资机构现身A股上市公司调研名单，合计调研9308 次。 具体来看，被称为"华尔街最疯狂赚钱机器"的Point 72资产管理公司今年以来调研A股上市公司263次， 排名首位。在2023和2024年，Point 72资产管理公司全年分别调研A股上市公司255次、259次，均为当 年外资调研榜第一位，堪称"A股调研劳模"。此外，高盛、美银证券、花旗环球等机构今年以来的调研 次数均超过100次。 从调研 ...

Group 1 - Nearly 800 foreign institutions have conducted approximately 9,308 research visits to A-share listed companies since 2025, with Point 72 Asset Management leading with 263 visits [1][2] - Major international banks such as Goldman Sachs and Bank of America have also conducted over 100 research visits this year [2][3] - The primary focus of foreign institutions is on the technology and pharmaceutical sectors, indicating strong interest in these areas [3][5] Group 2 - The top three companies receiving the most foreign institution research visits are Huichuan Technology (733 visits), Mindray Medical (404 visits), and Optoelectronics (331 visits) [3][4] - The technology sector, particularly AI, is expected to drive significant growth in corporate profits, with an estimated annual increase of 3% over the next decade due to cost savings and productivity improvements [5] - The pharmaceutical sector in China is gaining international recognition, with local innovative drug companies entering the global first tier in terms of research pipeline quantity [6]

Core Viewpoint - The "Quality Return Dual Improvement" initiative launched by the Shenzhen Stock Exchange aims to enhance the development quality and investment value return capabilities of listed companies, with 471 companies disclosing action plans by November 2025 [1][2]. Group 1: Company Participation and Focus Areas - Among the 471 companies, 293 are part of the Shenzhen Component Index, 88 are in the CSI 300 Index, and 82 belong to the ChiNext Index, collectively representing about 50% of the total market capitalization of the Shenzhen market [2]. - The companies involved span 30 industries, including electronics, power equipment, pharmaceuticals, and computers, with nearly 70% being private enterprises [2]. - The action plans of these companies emphasize three focal points: focusing on core business, focusing on technological innovation, and focusing on regulatory operations [2]. Group 2: Financial Performance and R&D Investment - In 2024, the "Dual Improvement" companies achieved a total operating revenue of 9.8 trillion yuan, a year-on-year increase of 3.6%, and a net profit of 743.39 billion yuan [4]. - For the first three quarters of 2025, these companies reported an operating revenue of 7.5 trillion yuan, up 6.9% year-on-year, and a net profit of 651.3 billion yuan, reflecting a 10.8% increase [4]. - The R&D investment of these companies accounted for 4.3% of their operating revenue in the first half of 2025, up 0.1 percentage points year-on-year, with total R&D expenditure representing 59.5% of the Shenzhen market [4]. Group 3: Shareholder Returns and Market Response - From 2022 to 2024, the annual total dividend of the "Dual Improvement" companies had a compound growth rate of 10.0%, with the 2024 dividend amounting to 43.6% of net profit, an increase of 10.9 percentage points from 2022 [5]. - Approximately 80% of the companies (378) maintained continuous dividends over the past three years, enhancing the stability and predictability of returns for investors [5]. - The average stock price increase for the 471 "Dual Improvement" companies from February 2024 to November 2025 was 77.2%, surpassing the growth of the Shenzhen Component Index [6].

Core Insights - The "Quality Return Dual Improvement" initiative launched by the Shenzhen Stock Exchange aims to enhance the development quality and investment value return capabilities of listed companies, with 471 companies having disclosed action plans by November 2025 [1][2] Group 1: Company Participation and Industry Coverage - Among the 471 companies, 293 are part of the Shenzhen Component Index, 88 are in the CSI 300 Index, and 82 belong to the ChiNext Index, collectively representing about 50% of the total market capitalization of Shenzhen [2] - The participating companies span 30 industries, including electronics, power equipment, pharmaceuticals, and computers, with a significant presence of private enterprises, accounting for nearly 70% of the participants [2] Group 2: Focus Areas of Improvement - The action plans from the listed companies emphasize three main focuses: enhancing core business awareness, improving technological innovation capabilities, and strengthening regulatory operations [2] - Specific examples include Mindray Medical (300760.SZ) increasing R&D investment and global expansion, and BYD (002594.SZ) planning R&D expenditures of 54.2 billion yuan in 2024 [2] Group 3: Shareholder Returns and Buybacks - Companies are increasing dividend and buyback efforts, with firms like BOE Technology Group (000725.SZ) disclosing future shareholder return plans, and Anke Bio (300009.SZ) maintaining 16 consecutive years of cash dividends [3] - The average annual dividend growth rate for "dual improvement" companies from 2022 to 2024 is 10.0%, with 2024 dividends accounting for 43.6% of net profits, a 10.9 percentage point increase from 2022 [5] Group 4: Financial Performance and Market Response - In terms of financial performance, "dual improvement" companies achieved a total revenue of 9.8 trillion yuan in 2024, a 3.6% year-on-year increase, and a net profit of 743.39 billion yuan [4] - The average stock price increase for these companies from February 2024 to November 2025 was 77.2%, surpassing the Shenzhen Component Index, with a total market capitalization of 21.2 trillion yuan by November 2025 [6]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 来源：创业邦 "只要一回到香港，就有一种到家的感觉。"11月下旬，在香港中环的一个写字楼上，张鹏（化名）看着 窗外的维多利亚港颇为感叹地说。 他曾经是一位知名的创业者、投资人，身价超过10亿人民币。几年前，因为在国内的一些纠纷，长期旅 居在海外，新加坡是他经常去的地方。今年初，他决定回到香港，"在新加坡时，虽然华人的氛围很浓 厚，但自己始终都是一个游客。" 过去几年，中国富豪在新加坡扎堆的现象备受关注，但最近，这个现象正在发生逆转，不少华人富豪开 始逃离新加坡，并选择香港作为他们的"主场"。 12月12日，致同香港会计师事务所发布的《香港财富管理热潮：引领全球市场新格局》，引发了不小的 关注。根据这份报告，今年上半年，资产超过3000万美元的高净值人士中，有17215人在香港，与2024 年同期相比，增加了22.9%。 香港也成为了全球顶级财富市场中增幅最大的地区。 而对于中国的富豪们来说，他们正集中面临着财富传承的难题。根据胡瑞百富《2022年中国高净值人群 家族传承报告》的预计，未来20年内，中国的高净值家庭约有92万亿人民币的财富 ...

以下文章来源于棱镜 ，作者吴遮 棱镜 . 腾讯新闻出品栏目，《棱镜》聚焦泛财经深度记录。 来源丨 棱镜 （ID： lengjing_qqfinance ） 作者丨 吴遮 编辑丨 孙春芳 图源丨Midjourney "只要一回到香港，就有一种到家的感觉。"11月下旬，在香港中环的一个写字楼上，张鹏（化名）看 着窗外的维多利亚港颇为感叹地说。 他曾经是一位知名的创业者、投资人，身价超过10亿人民币。几年前，因为在国内的一些纠纷，长期 旅居在海外，新加坡是他经常去的地方。今年初，他决定回到香港，"在新加坡时，虽然华人的氛围 很浓厚，但自己始终都是一个游客。" 过去几年，中国富豪在新加坡扎堆的现象备受关注，但最近，这个现象正在发生逆转，不少华人富豪 开始逃离新加坡，并选择香港作为他们的"主场"。 12月12日，致同香港会计师事务所发布的《香港财富管理热潮：引领全球市场新格局》，引发了不 小的关注。根据这份报告，今年上半年，资产超过3000万美元的高净值人士中，有17215人在香 港，与2024年同期相比，增加了22.9%。 香港也成为了全球顶级财富市场中增幅最大的地区。 而对于中国的富豪们来说，他们正集中面临着财富传 ...

Core Viewpoint - The medical device sector is experiencing a rebound, with significant inflows into the medical device ETF fund, indicating positive market sentiment and potential investment opportunities [1][3]. Group 1: Market Performance - The Shanghai Composite Index recorded a seven-day rise, with the medical device ETF fund (159797) increasing by 1.58% for two consecutive days [1]. - The medical device ETF fund has seen a net inflow for six consecutive days, accumulating over 31 million yuan in the last ten days [1]. - Most component stocks of the medical device ETF fund closed in the green, with notable gains from companies such as SINO Medical (up over 14%) and Xiangyu Medical (up over 6%) [3]. Group 2: Procurement Policy - The National Organization for High-Value Medical Consumables announced a centralized procurement document for drug-coated balloons and urological intervention consumables, with submission deadlines set for January 13, 2026 [3]. - The procurement cycle will last until December 31, 2028, indicating a long-term commitment to cost control in the medical device sector [3]. Group 3: Industry Outlook - The outlook for 2026 suggests a focus on innovation and international markets, with domestic demand expected to recover gradually [6]. - The medical device sector is anticipated to benefit from policy support and the increasing market share of leading companies, despite current pressures on domestic demand [6]. - The strategy for 2026 will emphasize overseas expansion and innovative products, which are expected to sustain profit margins amid price declines in traditional business areas [6]. Group 4: Specific Sector Insights - The medical device sector's growth will increasingly rely on domestic manufacturers' technological advancements and expansion into rural healthcare markets [7]. - The high-value consumables market is expected to see continued policy-driven changes, with a focus on optimizing bidding mechanisms and expanding product categories [7]. - The low-value consumables segment is adapting to global trade changes by accelerating overseas production to regain market share lost due to tariffs [8]. Group 5: Future Trends - The in-vitro diagnostics market is experiencing a shift towards domestic brands, which are gaining market share through competitive pricing and distribution advantages [8]. - The home medical device sector is prioritizing internationalization, with leading companies pursuing acquisitions and product registrations abroad to enhance growth prospects [8].

Group 1 - The core viewpoint of the articles highlights a significant upward movement in the medical device sector, driven by policy changes and market dynamics, with a particular focus on the launch of the sixth batch of high-value medical consumables procurement [1][2] - The medical device index ETF (159898) saw a 1.29% increase, with substantial purchases of 36 million units during trading, indicating strong investor interest [1] - Key stocks within the sector, such as SINO Medical and Mailland, experienced notable gains, with increases exceeding 14% and 11% respectively, reflecting positive market sentiment [1] Group 2 - The sixth batch of national high-value medical consumables procurement is set to begin on January 13, 2026, introducing new mechanisms to prevent malicious low pricing, including the concept of anchor pricing and a multi-revival mechanism [1] - The National Medical Products Administration has released new regulations to support medical device exports, which will take effect on May 1, 2026, aimed at optimizing the process for obtaining export sales certificates [1] - Northeast Securities predicts that 2026 will be a year of value reconstruction for the Chinese medical device sector, driven by improved cash flow in hospitals and expectations of policy optimization [2]

Core Viewpoint - The medical device sector is experiencing a positive shift, driven by new policies and market dynamics, with significant investment opportunities emerging as institutional holdings remain low [3][4]. Group 1: Market Performance - On December 25, major indices rose collectively, with the medical device index ETF (159898) increasing by 1.47%, attracting over 18 million yuan in net inflows during the session [1]. - Key stocks in the sector saw substantial gains, including Sino Medical up over 14%, and other notable increases from MaiLand and Weisi Medical [1]. Group 2: Policy Developments - A new round of national procurement for high-value medical consumables has been initiated, set to open bidding on January 13, 2026, focusing on drug-coated balloons and urological intervention consumables [2][3]. - The introduction of anchor pricing and a multi-revival mechanism in the sixth batch of procurement aims to balance price reductions and prevent malicious underpricing [3]. Group 3: Industry Outlook - The release of the "Regulations on the Management of Export Sales Certificates for Medical Devices" on December 25 is expected to support medical device exports, with implementation starting on May 1, 2026 [3]. - Northeast Securities predicts 2026 will be a year of value reconstruction for the medical device sector, with external pressures leading to improved cash flow for hospitals and procurement decisions [3]. - The medical device industry encompasses a wide range of products and services, with high barriers to entry in the core manufacturing and R&D segments [3]. Group 4: ETF Characteristics - The medical device index ETF (159898) tracks the CSI All-Share Medical Device Index, focusing on sectors such as medical equipment and consumables, with significant holdings in leading companies like Mindray and United Imaging [4]. - The index has a strong representation from the ChiNext and STAR Market, accounting for over 80% of its market cap, highlighting its growth-oriented characteristics [4].

Core Viewpoint - The ETF market is experiencing significant growth, highlighted by the recent launch of the HuShen 300 Enhanced Strategy ETF, which is expected to perform well amid a recovering A-share market [1][2]. Group 1: ETF Market Dynamics - The HuShen 300 Enhanced Strategy ETF (562070) is the second index-enhanced ETF launched by Huabao Fund in 2025, following the debut of the first "Chuangye Board Comprehensive Enhanced ETF" in August [2]. - The index-enhanced ETF category has evolved from a niche market to a competitive field with numerous participants, emphasizing the need for superior active management to achieve excess returns over benchmark indices [2][3]. - As of September 30, 2025, ETFs based on the HuShen 300 index accounted for over 30% of the total market size of stock-type ETFs, reinforcing its status as a core asset allocation choice in China [2]. Group 2: Performance and Management - The Huabao HuShen 300 Enhanced Fund, managed by Wang Zheng and Xu Linming, has demonstrated strong long-term performance, achieving a net value growth of 102.38% since its inception in December 2016, with an excess return of 51.04% over its benchmark [3][8]. - The fund has consistently outperformed its benchmark in 7 out of 8 years from 2017 to 2024, showcasing the effectiveness of the quantitative investment strategies developed by the management team [3][9]. - The management team has nearly 20 years of experience in quantitative investment, contributing to the fund's robust performance and the anticipated success of the newly launched HuShen 300 Enhanced Strategy ETF [3][8].